Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?

被引：0
|
作者：
Fabrizio Tabbò
Francesco Passiglia
Silvia Novello
机构：
[1] University of Turin,Department of Oncology
[2] San Luigi Hospital,undefined
来源：
Current Oncology Reports | 2021年 / 23卷
关键词：
ALK; Rearrangements; First-line; NSCLC; TKI; New-generation; Crizotinib; Ceritinib; Alectinib; Brigatinib; Lorlatinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Development of an ALK vaccine to treat ALK-rearranged non-small cell lung cancers
    Blasco, Rafael B.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [22] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Shaw, Alice T.
    Kim, Dong-Wan
    Mehra, Ranee
    Tan, Daniel S. W.
    Felip, Enriqueta
    Chow, Laura Q. M.
    Camidge, D. Ross
    Vansteenkiste, Johan
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin
    Liu, Geoffrey
    Santoro, Armando
    Lau, Yvonne Y.
    Goldwasser, Meredith
    Boral, Anthony L.
    Engelman, Jeffrey A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (13): : 1189 - 1197
  • [23] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Shen, Liang
    Ji, Hong-Fang
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (26): : 2537 - 2537
  • [24] Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus
    Cappuzzo, Federico
    Moro-Sibilot, Denis
    Gautschi, Oliver
    Boleti, Ekaterini
    Felip, Enriqueta
    Groen, Harry J. M.
    Germonpre, Paul
    Meldgaard, Peter
    Arriola, Edurne
    Steele, Nicola
    Fox, Jesme
    Schnell, Patrick
    Engelsberg, Arne
    Wolf, Juergen
    LUNG CANCER, 2015, 87 (02) : 89 - 95
  • [25] The Treatment Choice Based on Radiographic Features for Metastatic Brain Tumors in ALK-Rearranged Non-small Cell Lung Cancer
    Chu, L.
    Li, R.
    Yang, X.
    Xia, F.
    Zhang, X.
    Chu, J.
    Zhu, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E510 - E510
  • [26] Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer
    Ando, Chihiro
    Ichihara, Eiki
    Nishi, Tatsuya
    Morita, Ayako
    Hara, Naofumi
    Takada, Kenji
    Nakasuka, Takamasa
    Watanabe, Hiromi
    Kano, Hirohisa
    Nishii, Kazuya
    Makimoto, Go
    Kondo, Takumi
    Ninomiya, Kiichiro
    Fujii, Masanori
    Kubo, Toshio
    Ohashi, Kadoaki
    Matsuoka, Ken-ichi
    Hotta, Katsuyuki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    CANCER SCIENCE, 2023, 114 (11) : 4343 - 4354
  • [27] Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions
    Laird Cameron
    Benjamin Solomon
    Drugs, 2015, 75 : 1059 - 1070
  • [28] New Strategies for Treatment of ALK-Rearranged Non-Small Cell Lung Cancers
    Sasaki, Takaaki
    Jaenne, Pasi A.
    CLINICAL CANCER RESEARCH, 2011, 17 (23) : 7213 - 7218
  • [29] ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism
    Zer, Alona
    Moskovitz, Mor
    Hwang, David
    Hershko-Klement, Anat
    Fridel, Ludmila
    Korpanty, Grzegorz
    Dudnik, Elizabeth
    Peled, Nir
    Shochat, Tzippy
    Leighl, Natasha
    Liu, Geoffrey
    Feld, Ronald
    Burkes, Ronald
    Wollner, Mira
    Tsao, Ming
    Shepherd, Frances
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S326 - S327
  • [30] Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Kate McKeage
    Drugs, 2015, 75 : 75 - 82
12345